nach oben

Inflammopharmacology

Erschienen in:

14.10.2020 | Review

Neuroinflammatory responses in Parkinson’s disease: relevance of Ibuprofen in therapeutics

verfasst von: Ashish Singh, Pratibha Tripathi, Sarika Singh

Erschienen in: Inflammopharmacology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Parkinson’s disease (PD) pathogenesis inevitably involves neuroinflammatory responses attained through contribution of both neuron and glial cells. Investigation done in both experimental models of PD and in samples of PD patients suggested the involvement of both central and peripheral inflammatory responses during PD pathogenesis. Such neuroinflammatory responses could be regulated by neuron-glia interaction which is one of the recently focused areas in the field of disease diagnosis, pathogenesis and therapeutics. Such aggravated neuroinflammatory responses during PD are very well associated with augmented levels of cyclooxygenase (COX). An increased expression of cyclooxygenase (COX) with a concomitant increase in the prostaglandin E2 (PGE2) levels has been observed during PD pathology. Ibuprofen is one of the non-steroidal anti-inflammatory drugs (NSAID) and clinically being used for PD patients. This review focuses on the neuroinflammatory responses during PD pathology as well as the effect of ibuprofen on various disease related signaling factors and mechanisms involving nitrosative stress, neurotransmission, neuronal communication and peroxisome proliferator-activated receptor-γ. Such mechanistic effect of ibuprofen has been mostly reported in experimental models of PD and clinical investigations are still required. Since oxidative neuronal death is one of the major neurodegenerative mechanisms in PD, the antioxidant capacity of ibuprofen along with its antidepressant effects have also been discussed. This review will direct the readers towards fulfilling the existing gaps in the mechanistic aspect of ibuprofen and enhance its clinical relevance in PD therapeutics and probably in other age-related neurodegenerative diseases.

Aeberhard EE, Henderson SA, Arabolos NS, Griscavage JM, Castro FE, Barrett CT, Ignarro LJ (1995) Nonsteroidal anti-inflammatory drugs inhibit expression of the inducible nitric oxide synthase gene. Biochem Biophys Res Commun 208(3):1053–1059. https://doi.org/10.1006/bbrc.1995.1441CrossRefPubMed

Ajmone-Cat MA, Bernardo A, Greco A, Minghetti L (2010) Non-steroidal anti-inflammatory drugs and brain inflammation: effects on microglial functions. Pharmaceuticals (Basel) 3(6):1949–1965

Ardestani MS (2010) Parkinson's disease, the inflammatory pathway and anti-inflammatory drug: an overview. J Med Sci 10(3):49–58

Asanuma M, Miyazaki I (2007) Common anti-inflammatory drugs are potentially therapeutic for Parkinson’s disease? Exp Neurol 206(2):172–178PubMed

Bartels AL, Leenders KL (2010) Cyclooxygenase and neuroinflammation in Parkinson’s disease neurodegeneration. Curr Neuropharmacol 8:62–68PubMedPubMedCentral

Booth HDE, Hirst WD, Wade-Martins R (2017) The role of astrocyte dysfunction in Parkinson's disease pathogenesis. Trends Neurosci 40(6):358–370PubMedPubMedCentral

Bordet R, Ouk T, Petrault O, Gelé P, Gautier S, Laprais M, Deplanque D, Duriez P, Staels B, Fruchart JC, Bastide M (2006) PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. BiochemSoc Trans 34(Pt 6):1341–1346

Bové J, Prou D, Perier C, Przedborski S (2005) Toxin-induced models of Parkinson's disease. NeuroRx 2(3):484–494PubMedPubMedCentral

Bozyczko-Coyne D, Williams M (2007) Therapeutic areas I: central nervous system, pain, metabolic syndrome, urology, gastrointestinal and cardiovascular. Comprehen Med Chem 6:193–228

Brück D, Wenning GK, Stefanova N, Fellner L (2016) Glia and alpha-synuclein in neurodegeneration: a complex interaction. Neurobiol Dis 85:262–274PubMed

Bushra R, Aslam N (2010) An overview of clinical pharmacology of Ibuprofen. Oman Med J 25(3):155–1661PubMedPubMedCentral

Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA, Stella AM (2007) Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat Rev Neurosci 8(10):766–775PubMed

Carvalho KM, Winter E, Antunes AMDS (2015) Evaluation of development of R&D into Parkinson’s disease through technology monitoring using patent documents and scientific articles. Intern J Res Pharm Biosci 2(3):17–24

Casper D, Yaparpalvi U, Rempel N, Werner P (2000) Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro. NeurosciLett 289:201–204

Chao Y, Wong SC, Tan EK (2014) Evidence of inflammatory system involvement in Parkinson’s disease. Biomed Res Int 14:308654

Chaturvedi RK, Beal MF (2008) PPAR: a therapeutic target in Parkinson’s disease. J Neurochem 106(2):506–518PubMed

Chen H, Zhang SM (2003) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60:1059–1064PubMed

Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A (2005) Nonsteroidal anti-inflammatory drug use and the risk for Parkinson's disease. Ann Neurol 58:963–967PubMed

Chen WW, Zhang X, Huang WJ (2016) Role of neuroinflammation in neurodegenerative diseases (Review). Mol Med Rep 13(4):3391–3396PubMedPubMedCentral

Choi Y, Lee MK, Lim SY, Sung SH, Kim YC (2009) Inhibition of inducible NO synthase, cyclooxygenase-2 and interleukin-1beta by torilin is mediated by mitogen-activated protein kinases in microglial BV2 cells. Br J Pharmacol 156(6):933–940PubMedPubMedCentral

Colafrancesco V, Villoslada P (2011) Targeting NGF-pathway for developing neuroprotective therapies for multiple sclerosis and other neurological diseases. Arch Biol 149:183–192

Contestabile A, Monti B, Polazzi E (2012) Neuronal-glial interactions define the role of nitric oxide in neural functional processes. Curr Neuropharmacol 10(4):303–310PubMedPubMedCentral

Corwin C, Nikolopoulou A, Pan AL, Nunez-Santos M, Vallabhajosula S, Serrano P, Figueiredo-Pereira ME (2018) Prostaglandin D2/J2 signaling pathway in a rat model of neuroinflammation displaying progressive parkinsonian-like pathology: potential novel therapeutic targets. J Neuroinflam 15(1):272. https://doi.org/10.1186/s12974-018-1305-3CrossRef

Croisier E, Moran LB, Dexter DT, Pearce RK, Graeber MB (2005) Microglial inflammation in the parkinsoniansubstantianigra: relationship to alpha-synuclein deposition. J Neuroinflam 3(2):14

Członkowska A, Kurkowska-Jastrzebska I, Członkowski A, Peter D, Stefano GB (2002) Immune processes in the pathogenesis of Parkinson's disease - a potential role for microglia and nitric oxide. Med Sci Monitor Internat Med J Experiment Clin Res 8(8):165–177

Dannoura A, Giraldo A, Pereira I, Gibbins JM, Dash PR, Bicknell KA, Brooks G (2014) Ibuprofen inhibits migration and proliferation of human coronary artery smooth muscle cells by inducing a differentiated phenotype: role of peroxisome proliferator-activated receptor γ. J Pharm Pharmacol 66(6):779–792. https://doi.org/10.1111/jphp.12203CrossRefPubMed

Desvergne B, Wahli W (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20(5):649–688PubMed

Dias V, Junn E, Mouradian MM (2013) The role of oxidative stress in Parkinson’s disease. J Parkinsons Dis 3(4):461–491PubMedPubMedCentral

Dixit A, Srivastava G, Verma D, Mishra M, Singh PK, Prakash O, Singh MP (2013) Minocycline, levodopa and MnTMPyP induced changes in the mitochondrial proteome profile of MPTP and maneb and paraquat mice models of Parkinson's disease. Biochim Biophys Acta 1832(8):1227–1240PubMed

Dringen R, Pfeiffer B, Hamprecht B (1999) Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione. J Neurosci Off Soc Neurosci 19(2):562–569. https://doi.org/10.1523/JNEUROSCI.19-02-00562.1999CrossRef

Elsisi NS, Darling-Reed S, Lee EY, Oriaku ET, Soliman KF (2005) Ibuprofen and apigenin induce apoptosis and cell cycle arrest in activated microglia. Neurosci Lett 375(2):91–96. https://doi.org/10.1016/j.neulet.2004.10.087CrossRefPubMed

Esplugues JV (2002) NO as a signalling molecule in the nervous system. Br J Pharmacol 135(5):1079–1095PubMedPubMedCentral

Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G (2007) Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol 205(2):295–312PubMed

Farooqui AA, Horrocks LA, Farooqui T (2007) Modulation of inflammation in brain: a matter of fat. J Neurochem 101(3):577–599PubMed

Förstermann U, Sessa WC (2012) Nitric oxide synthases: regulation and function. Eur Heart J 33(7):829–837PubMed

Fu R, Shen Q, Xu P, Luo JJ, Tang Y (2014) Phagocytosis of microglia in the central nervous system diseases. Mol Neurobiol 49(3):1422–1434PubMedPubMedCentral

Gagne JJ, Power MC (2010) Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 74(12):995–1002. https://doi.org/10.1212/WNL.0b013e3181d5a4a3CrossRefPubMedPubMedCentral

Gao X, Chen H, Schwarzschild MA, Ascherio A (2011) Use of ibuprofen and risk of Parkinson disease. Neurology 76(10):863–869PubMedPubMedCentral

Giráldez-Pérez R, Antolín-Vallespín M, Muñoz M, Sánchez-Capelo A (2014) Models of α-synuclein aggregation in Parkinson’s disease. Acta Neuropathol Commun 13(2):176

Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140(6):918–934PubMedPubMedCentral

Graeber MB, Li W, Rodriguez ML (2011) Role of microglia in CNS inflammation. FEBSLett 585(23):3798–3805

Griffiths MR, Gasque P, Neal JW (2010) The regulation of the CNS innate immune response is vital for the restoration of tissue homeostasis (repair) after acute brain injury: a brief review. Int J Inflam 9:151097

Hartmann A (2004) Postmortem studies in Parkinson’s disease. Dialogues ClinNeurosci 6(3):281–293

Hastings TG (1995) Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 64(2):919–924. https://doi.org/10.1046/j.1471-4159.1995.64020919.xCrossRefPubMed

Heneka MT (2019) Microglia take centre stage in neurodegenerative disease. Nat Rev Immunol 19(2):79–80. https://doi.org/10.1038/s41577-018-0112-5CrossRefPubMed

Heneka MT, Landreth GE (2007) PPARs in the brain. Biochim Biophys Acta 1771(8):1031–1045PubMed

Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O'Banion K, Klockgether T, Van Leuven F, Landreth GE (2005) Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1–42 levels in APPV717I transgenic mice. Brain j neurol 128(6):1442–1453. https://doi.org/10.1093/brain/awh452CrossRef

Hernandez-Baltazar D, Zavala-Flores LM, Villanueva-Olivo A (2017) The 6-hydroxydopamine model and parkinsonian pathophysiology: novel findings in an older model. Neurología 32(8):533–539PubMed

Hsieh YC, Mounsey RB, Teismann P (2011) MPP(+)-induced toxicity in the presence of dopamine is mediated by COX-2 through oxidative stress. NaunynSchmiedebergs Arch Pharmacol 384(2):157–167

Isacson O, Brundin P, Gage FH, Björklund A (1985) Neural grafting in a rat model of Huntington’s disease: progressive neurochemical changes after neostriatal ibotenate lesions and striatal tissue grafting. Neuroscience 16(4):799–817. https://doi.org/10.1016/0306-4522(85)90095-8CrossRefPubMed

Jamali F, Brocks DR (2015) The Pharmacokinetics of Ibuprofen in Humans and Animals. In: Rainsford KD (ed) Ibuprofen: Discovery. Development and Therapeutics, First Edition, pp 81–130

Jaradat MS, Wongsud B, Phornchirasilp S, Rangwala SM, Shams G, Sutton M, Romstedt KJ, Noonan DJ, Feller DR (2001) Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H(2) synthases by ibuprofen, naproxen, and indomethacin. Biochem Pharmacol 62(12):1587–1595. https://doi.org/10.1016/s0006-2952(01)00822-xCrossRefPubMed

Jeong HK, Jou I, Joe EH (2010) Systemic LPS administration induces brain inflammation but not dopaminergic neuronal death in the substantianigra. ExpMol Med 42(12):823–832

Joshi N, Singh S (2018) Updates on immunity and inflammation in Parkinson disease pathology. J Neurosci Res 96(3):379–390. https://doi.org/10.1002/jnr.24185CrossRefPubMed

Kapadia R, Yi JH, Vemuganti R (2008) Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci J Virt Lib 13:1813–1826. https://doi.org/10.2741/2802CrossRef

Kaufmann WE, Worley PF, Pegg J, Bremer M, Isakson P (1996) COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci U S A 93:2317–2321PubMedPubMedCentral

Kim YS, Joh TH (2006) Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson’s disease. ExpMol Med 38(4):333–347

Knott AB, Bossy-Wetzel E (2009) Nitric oxide in health and disease of the nervous system. Antioxid Redox Signal 11(3):541–554PubMedPubMedCentral

Kraft AD, Harry GJ (2011) Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity. Int J Environ Res Public Health 8(7):2980–3018PubMedPubMedCentral

Lawrence T (2009) The nuclear factor NF-kappaB pathway in inflammation. Cold Spring HarbPerspect Biol 1(6):a001651

Lee JA, Song HY, Ju SM, Lee SJ, Kwon HJ, Eum WS, Jang SH, Choi SY, Park JS (2009) Differential regulation of inducible nitric oxide synthase and cyclooxygenase-2 expression by superoxide dismutase in lipopolysaccharide stimulated RAW 264.7 cells. Exp Mol Med 41(9):629–637PubMedPubMedCentral

Longhena F, Faustini G, Missale C, Pizzi M, Spano P, Bellucci A (2017) The contribution of α-Synuclein spreading to Parkinson's DiseaseSynaptopathy. Neural Plast 2017:5012129PubMedPubMedCentral

Lull ME, Block ML (2010) Microglial activation and chronic neurodegeneration. Neurotherapeutics 7(4):354–365PubMedPubMedCentral

Mandal S, Mandal SD, Chuttani K, Sawant KK, Subudhi BB (2018) Preclinical study of ibuprofen loaded transnasal mucoadhesive microemulsion for neuroprotective effect in MPTP mice model. Iran J Pharma Res IJPR 17(1):23–38

McGeer PL, McGeer EG (2004) Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 10(Suppl 1):S3–7PubMed

McGeer E, Yasojima K, McGeer LP (2001) Inflammation in the pathogenesis of Parkinson’s disease. BCMJ 3:138–141

Menzel-Soglowek S, Geisslinger G, Brune K (1990) Stereoselective high-performance liquid chromatographic determination of ketoprofen, ibuprofen and fenoprofen in plasma using a chiral alpha 1-acid glycoprotein column. J Chromatogr 532(2):295–303. https://doi.org/10.1016/s0378-4347(00)83780-9CrossRefPubMed

Minghetti L (2004) Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 63(9):901–910PubMed

Minghetti L, Nicolini A, Polazzi E, Créminon C, Maclouf J, Levi G (1997) Inducible nitric oxide synthase expression in activated rat microglial cultures is downregulated by exogenous prostaglandin E2 and by cyclooxygenase inhibitors. Glia 19(2):152–160PubMed

Moore AH, Bigbee MJ, Boynton GE, Wakeham CM, Rosenheim HM, Staral CJ, Morrissey JL, Hund AK (2010) Non-steroidal anti-inflammatory drugs in Alzheimer’s Disease and Parkinson's Disease: reconsidering the role of neuroinflammation. Pharmaceuticals (Basel) 3(6):1812–1841

More SV, Kumar H, Kim IS, Song SY, Choi DK (2013) Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease. Med Inflamm 2013:952375

Mosley RL, Benner EJ, Kadiu I, Thomas M, Boska MD, Hasan K, Laurie C, Gendelman HE (2006) Neuroinflammation, oxidative stress and the pathogenesis of Parkinson’s disease. Clin Neuro sci Res 6(5):261–281

Naeem S, Ikram R, Khan SS, Rao SS (2017) NSAIDs ameliorate cognitive and motor impairment in a model of parkinsonism induced by chlorpromazine. Pakistan J Pharma Sci 30(3):801–808

Nikolic D, van Breemen RB (2001) DNA oxidation induced by cyclooxygenase-2. Chem Res Toxicol 14(4):351–354. https://doi.org/10.1021/tx010004xCrossRefPubMed

Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T (2005) Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol 57(2):168–175. https://doi.org/10.1002/ana.20338CrossRefPubMed

Peferoen L, Kipp M, van der Valk P, van Noort JM, Amor S (2014) Oligodendrocyte-microglia cross-talk in the central nervous system. Immunology 141(3):302–313PubMedPubMedCentral

Perry VH (2012) Innate inflammation in Parkinson’s disease. Cold Spring HarbPerspect Med 2(9):a009373

Perry VH, Teeling J (2013) Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration. Semin Immunopathol 35(5):601–612PubMedPubMedCentral

Radtke FA, Chapman G, Hall J, Syed YA (2017) Modulating neuroinflammation to treat neuropsychiatric disorders. Biomed Res Int 2017:5071786. https://doi.org/10.1155/2017/5071786CrossRefPubMedPubMedCentral

Rainsford KD (2012) Ibuprofen: Pharmacology. Therapeutics and Side Effects, Springer, Heidelberg New York Dordrecht London

Ramazani E, Tayarani-Najaran Z, Fereidoni M (2019) Celecoxib, indomethacin, and ibuprofen prevent 6-hydroxydopamine-induced PC12 cell death through the inhibition of NFκB and SAPK/JNK pathways. Iran J Basic Med Sci 22(5):477–484. https://doi.org/10.22038/IJBMS.2019.34011.8091CrossRefPubMedPubMedCentral

Recasens A, Dehay B (2014) Alpha-synuclein spreading in Parkinson's disease. Front Neuroanat 18(8):159

Ren L, Yi J, Yang J, Li P, Cheng X, Mao P (2018) Nonsteroidal anti-inflammatory drugs use and risk of Parkinson disease: A dose-response meta-analysis. Medicine 97(37):e12172. https://doi.org/10.1097/MD.0000000000012172CrossRefPubMedPubMedCentral

Ricciotti E, FitzGerald GA (2011) Prostaglandins and inflammation. Arterioscler Throm Vasc Biol 31(5):986–1000

Rock RB, Gekker G, Hu S, Sheng WS, Cheeran M, Lokensgard JR, Peterson PK (2004) Role of microglia in central nervous system infections. ClinMicrobiol Rev 17(4):942–964

Saha RN, Pahan K (2006) Regulation of inducible nitric oxide synthase gene in glial cells. Antioxid Redox Signal 8(5–6):929–947PubMed

Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman P (1993) Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 90(15):7240–7244PubMedPubMedCentral

Sánchez-Pernaute R, Ferree A, Cooper O, Yu M, Brownell AL, Isacson O (2004) Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J Neuroinflam 1(1):6. https://doi.org/10.1186/1742-2094-1-6CrossRef

Schiefer J, Kampe K, Dodt HU, Zieglgänsberger W, Kreutzberg GW (1999) Microglial motility in the rat facial nucleus following peripheral axotomy. J Neurocytol 28(6):439–453. https://doi.org/10.1023/a:1007048903862CrossRefPubMed

Simmons DL, Botting RM, Hla T (2004) Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56(3):387–437PubMed

Singh S, Swarnkar S, Goswami P, Nath C (2011) Astrocytes and microglia: responses to neuropathological conditions. Internat J Neurosci 121(11):589–597. https://doi.org/10.3109/00207454.2011.598981CrossRef

Singh AK, Tiwari MN, Upadhyay G, Patel DK, Singh D, Prakash O, Singh MP (2012) Long term exposure to cypermethrin induces nigrostriatal dopaminergic neurodegeneration in adult rats: postnatal exposure enhances the susceptibility during adulthood. Neurobiol Aging 33:404–415PubMed

Singh A, Tripathi P, Prakash O, Singh MP (2016) Ibuprofen abates cypermethrin-induced expression of pro-inflammatory mediators and mitogen-activated protein kinases and averts the nigrostriatal dopaminergic neurodegeneration. MolNeurobiol 53:6849–6858

Sochocka M, Diniz BS, Leszek J (2017) Inflammatory response in the CNS: friend or Foe? MolNeurobiol 54(10):8071–8089

Srivastava G, Dixit A, Yadav S, Patel DK, Prakash O, Singh MP (2012) Resveratrol potentiates cytochrome P450 2 d22-mediated neuroprotection in maneb- and paraquat-induced parkinsonism in the mouse. Free RadicBiol Med 52(8):1294–1306

Stefanis L (2012) α-Synuclein in Parkinson's disease. Cold Spring HarbPerspect Med 2(2):a009399

Stratman NC, Carter DB, Sethy VH (1997) Ibuprofen: effect on inducible nitric oxide synthase. Brain Res Mol Brain Res 50(1–2):107–112. https://doi.org/10.1016/s0169-328x(97)00168-xCrossRefPubMed

Straus DS, Glass CK (2001) Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev 21:185–210PubMed

Su X, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K, Federoff HJ (2008) Synuclein activates microglia in a model of Parkinson's disease. Neurobiol Aging 29(11):1690–1701PubMed

Takeuchi H, Mizuno T, Zhang G, Wang J, Kawanokuchi J, Kuno R, Suzumura A (2005) Neuritic beading induced by activated microglia is an early feature of neuronal dysfunction toward neuronal death by inhibition of mitochondrial respiration and axonal transport. J Biol Chem 280(11):10444–10454. https://doi.org/10.1074/jbc.M413863200CrossRefPubMed

Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37(3):510–518PubMed

Teismann P (2012) COX-2 in the neurodegenerative process of Parkinson’s disease. BioFactors (Oxford, England) 38(6):395–397. https://doi.org/10.1002/biof.1035CrossRef

Theodore S, Cao S, McLean PJ, Standaert DG (2008) Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol 67(12):1149–1158PubMed

Tripathi P, Singh A, Bala L, Patel DK, Singh MP (2018) Ibuprofen protects from cypermethrin-induced changes in the striatal dendritic length and Spine Density. MolNeurobiol MolNeurobiol 55(3):2333–2339

Tsuji T, Asanuma M, Miyazaki I, Miyoshi K, Ogawa N (2009) Reduction of nuclear peroxisome proliferator-activated receptor gamma expression in methamphetamine-induced neurotoxicity and neuroprotective effects of ibuprofen. Neurochem Res 34:764–774PubMed

Tufekci KU, Genc S, Genc K (2011) The endotoxin-induced neuroinflammation model of Parkinson’s disease. Parkinsons Dis 18:487–450

Tuteja N, Chandra M, Tuteja R, Misra MK (2004) Nitric oxide as a unique bioactive signaling messenger in physiology and pathophysiology. J Biomed Biotechnol 4:227–237

Uttara B, Singh AV, Zamboni P, Mahajan RT (2009) Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol 7(1):65–74PubMedPubMedCentral

Van Antwerpen P, Nève J (2004) In vitro comparative assessment of the scavenging activity against three reactive oxygen species of non-steroidal anti-inflammatory drugs from the oxicam and sulfoanilide families. Eur J Pharmacol 496(1–3):55–61. https://doi.org/10.1016/j.ejphar.2004.06.017CrossRefPubMed

Vijitruth R, Liu M, Choi DY, Nguyen XV, Hunter RL, Bing G (2006) Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson’s disease. J Neuroinflam 3:6. https://doi.org/10.1186/1742-2094-3-6CrossRef

Volpe BT, Wildmann J, Altar CA (1998) Brain-derived neurotrophic factor prevents the loss of nigral neurons induced by excitotoxic striatal-pallidal lesions. Neuroscience 83(3):741–748. https://doi.org/10.1016/s0306-4522(97)00424-7CrossRefPubMed

Wang Q, Liu Y, Zhou J (2015) Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. Transl Neurodegen 12(4):19

Wilkinson BL, Landreth GE (2006) The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. J Neuroinflam 9(3):30

Wnuk A, Kajta M (2017) Steroid and xenobiotic receptor signalling in apoptosis and autophagy of the nervous system. Int J Mol Sci 18(11):E2394PubMed

Wu KK (2010) peroxisome proliferator-activated receptors protect against apoptosis via 14-3-3. PPAR Res 2:417646

Yadav S, Dixit A, Agrawal S, Singh A, Srivastava G, Singh AK, Srivastava PK, Prakash O, Singh MP (2012) Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis. MolNeurobiol 46(2):495–512

Yan J, Fu Q, Cheng L, Zhai M, Wu W, Huang L, Du G (2014) Inflammatory response in Parkinson’s disease (Review). Mol Med Rep 10(5):2223–2233PubMed

Yonutas HM, Sullivan PG (2013) Targeting PPAR isoforms following CNS injury. Curr Drug Targets 14(7):733–742. https://doi.org/10.2174/1389450111314070003CrossRefPubMed

Zaminelli T, Gradowski RW, Bassani TB, Barbiero JK, Santiago RM, Maria-Ferreira D, Baggio CH, Vital MA (2014) Antidepressant and antioxidative effect of Ibuprofen in the rotenone model of Parkinson’s disease. Neurotox Res 26(4):351–362PubMed

Zawada WM, Banninger GP, Thornton J, Marriott B, Cantu D, Rachubinski AL, Das M, Griffin WS, Jones SM (2011) Generation of reactive oxygen species in 1-methyl-4-phenylpyridinium (MPP+) treated dopaminergic neurons occurs as an NADPH oxidase-dependent two-wave. Cascade J Neuroinflam 8:129

Titel: Neuroinflammatory responses in Parkinson’s disease: relevance of Ibuprofen in therapeutics
verfasst von: Ashish Singh
Pratibha Tripathi
Sarika Singh
Publikationsdatum: 14.10.2020
Verlag: Springer International Publishing
Erschienen in: Inflammopharmacology / Ausgabe 1/2021
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-020-00764-w

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Effect of canakinumab on clinical and biochemical parameters in acute gouty arthritis: a meta-analysis

Memantine and Ibuprofen pretreatment exerts anti-inflammatory effect against streptozotocin-induced astroglial inflammation via modulation of NMDA receptor-associated downstream calcium ion signaling

NSAID-enteropathy and intestinal microbes

The anti-inflammatory role of SSRI and SNRI in the treatment of depression: a review of human and rodent research studies

MiR-200a inversely correlates with Hedgehog and TGF-β canonical/non-canonical trajectories to orchestrate the anti-fibrotic effect of Tadalafil in a bleomycin-induced pulmonary fibrosis model

Pharmacodynamic mechanisms of anti-inflammatory drugs on the chemosensitization of multidrug-resistant cancers and the pharmacogenetics effectiveness